Can You Reverse Cognitive Decline?

Sam Altman's $1.8B Longevity Company, CRISPR & AI Health | Longevity News Roundup — Week 22, 2026

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [ https://qrco.de/bgXpKn] ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: https://partners.fatty15.com/UNLOCKED [https://partners.fatty15.com/UNLOCKED] ---------- In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine FDA-cleared sleep diagnostics, safer CRISPR therapies, longevity clinic accountability, Retro Biosciences’ valuation, and AI-driven preventative healthcare. * Sunrise received FDA clearance for Sunrise Air, a rechargeable at-home sleep apnea diagnostic using a chin sensor for multi-night testing. The device tracks airflow, oxygen, pulse, and snoring while targeting underdiagnosis linked to cardiovascular and cognitive decline. * Insilico and Human Longevity have announced a multimillion-dollar collaboration to build what they describe as the industry’s first large-scale AI foundation model dedicated to longevity science.  * Daewoong Pharmaceutical acquired Turn Biotechnologies’ partial reprogramming assets, including its ERA mRNA platform. The deal gives longevity-focused age reversal IP a new clinical and regulatory pathway. * Scribe Therapeutics presented preclinical ELXR CRISPR data showing 18-month cholesterol reduction in primates through epigenetic PCSK9 silencing. The platform reduced off-target activity by up to 100-fold without permanently altering DNA. * At the Milan Longevity Summit 2026 they explored how longevity clinics are moving from wellness branding toward evidence-based preventative medicine. Clinics are increasingly being pressured to prove outcomes through validated biomarkers and longitudinal patient data. * Retro Biosciences reached a $1.8 billion valuation while advancing an Alzheimer’s drug into human trials. Retro’s approach focuses on boosting a natural cellular process called autophagy, essentially the body’s built-in recycling program. ---------- News & References: * Retro Bio’s $1.8b moment: Hopes up as Alzheimer’s trial advances → https://longevity.technology/news/retro-bios-1-8b-moment-hopes-up-as-alzheimers-trial-advances/ [https://longevity.technology/news/retro-bios-1-8b-moment-hopes-up-as-alzheimers-trial-advances/] * Longevity clinics face their proving ground → https://longevity.technology/news/longevity-clinics-face-their-proving-ground/ [https://longevity.technology/news/longevity-clinics-face-their-proving-ground/] * Sunrise receives FDA clearance for rechargeable at-home sleep test → https://longevity.technology/news/sunrise-receives-fda-clearance-for-rechargeable-at-home-sleep-test/ [https://longevity.technology/news/sunrise-receives-fda-clearance-for-rechargeable-at-home-sleep-test/] * Daewoong acquires Turn Bio age-reversal assets → https://longevity.technology/news/daewoong-acquires-turn-bio-age-reversal-assets/ [https://longevity.technology/news/daewoong-acquires-turn-bio-age-reversal-assets/] * Scribe Therapeutics debuts CRISPR platforms for cholesterol treatment → https://longevity.technology/news/scribe-therapeutics-debuts-crispr-platforms-for-cholesterol-treatment/ [https://longevity.technology/news/scribe-therapeutics-debuts-crispr-platforms-for-cholesterol-treatment/] * Insilico and Human Longevity eye to predict disease early with AI → https://longevity.technology/news/insilico-and-human-longevity-eye-to-predict-disease-early-with-ai/ [https://longevity.technology/news/insilico-and-human-longevity-eye-to-predict-disease-early-with-ai/]

This Wearable Tracks the Female Cycle in Real Time

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [https://qrco.de/bgXpKn] ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: fatty15.com/UNLOCKED [https://fatty15.com/UNLOCKED] ---------- Guests: Jenny Duan Co-Founder and CEO of Clair Health LinkedIn: https://www.linkedin.com/in/jennysduan/ [https://www.linkedin.com/in/jennysduan/] Website: https://wearclair.com/ [https://wearclair.com/] Abhinav Agarwal Co-Founder and CTO of Clair Health LinkedIn: https://www.linkedin.com/in/agarwalaabhinav/ [https://www.linkedin.com/in/agarwalaabhinav/] Website: https://wearclair.com/ [https://wearclair.com/] ---------- What if women’s hormones were tracked like heart rate, continuously and contextually, not through annual snapshots? Phil Newman and Dr. Nina Patrick sit down with Jenny Duan, CEO of Clair, and Abhinav Argawal, CTO, to explore how a jewelry-inspired wrist wearable uses multi-sensor biosignals to infer estrogen and progesterone in real time across daily life. They explain how signals such as skin temperature, HRV, sweat response, intracellular and extracellular current shifts, and more than 100 derived biomarkers are combined through sensor fusion to model hormone trajectories that update throughout the day. From forecasting an athlete’s rate of perceived exertion days before training to identifying progesterone patterns associated with PCOS and endometriosis risk, these examples show what continuous data reveals that snapshot testing cannot. The discussion also uncovers how this level of visibility allows the female cycle to be understood as nine distinct sub-phases rather than the traditional four. They also discuss how lifestyle context, such as sleep, hydration, stress, and schedule, is integrated into the model to avoid contradictions between device feedback and lived experience. Early beta studies across PCOS, endometriosis, and perimenopause cohorts are already informing how this data can support fertility planning and symptom awareness. In this episode, you’ll learn: * Why the female cycle can be divided into nine hormone sub-phases * How 230 biomarkers are refined into 100 inputs for hormone modeling * How athletes can adjust hydration and nutrition before exertion spikes * How progesterone trends may signal risk patterns for PCOS and endometriosis * Why fertility and perimenopause represent 60% of early pre-orders If you want to understand how continuous hormone visibility reshapes female health decisions across life stages, this episode connects biosensing, AI modeling, and practical insights for longevity. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

GLP‑1 Gene Therapy: A One‑Time Fix for Obesity & Diabetes? | Longevity News Roundup — Week 21, 2026

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [https://qrco.de/bgXpKn] ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: https://partners.fatty15.com/UNLOCKED [https://partners.fatty15.com/UNLOCKED] ---------- In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick examine pancreatic cancer immunotherapy, GLP-1 gene therapy, immune system rebuilding, cardiovascular plaque reversal and microbiome medicine. * MatterBio filed its first IND application for Lm-LLO-TT, an engineered Listeria-based therapy targeting pancreatic ductal adenocarcinoma. Pending FDA clearance, the company plans a Phase 1/2a study evaluating safety, dosing and early efficacy in advanced pancreatic cancer patients resistant to conventional immunotherapy. * Fractyl Health received European approval to begin a first-in-human Phase 1/2 trial of RJVA-001, GLP-1 gene therapy for obesity and type 2 diabetes. The therapy uses endoscopic ultrasound-guided pancreatic delivery to program beta cells to produce GLP-1 in response to meals rather than relying on repeated injections. * Ossium Health presented clinical trial data showing successful engraftment using cryopreserved bone marrow collected from deceased organ donors. Researchers believe the banking platform could eventually simplify bone marrow transplantation logistics and expand future immune system renewal applications. * Cyclarity shared new progress on therapies targeting 7-ketocholesterol, an oxidized cholesterol molecule linked to plaque instability and chronic arterial inflammation. Rather than slowing plaque growth, the company aims to physically remove toxic cholesterol deposits already embedded within blood vessel walls. * Microbiotica reported positive Phase 1b MELODY-1 trial data for MB097, a microbiome therapy containing nine bacterial strains combined with KEYTRUDA in advanced melanoma patients. The therapy showed successful gut engraftment and encouraging signals that microbiome modulation may help overcome immunotherapy resistance. * The episode also explored health equity in longevity medicine with Poonam Desai ahead of The Longevity Show. Discussions focused on sex-specific medicine, unequal access to longevity care and the risks of building precision health systems around biased clinical data. ---------- News & References: * ‘Rebuilding the human immune system is possible’ → https://longevity.technology/news/rebuilding-the-human-immune-system-is-possible/ [https://longevity.technology/news/rebuilding-the-human-immune-system-is-possible/] * Fractyl Health to begin EU trials for one-time weight loss gene therapy → https://longevity.technology/news/fractyl-health-to-begin-eu-trials-for-one-time-weight-loss-gene-therapy/ [https://longevity.technology/news/fractyl-health-to-begin-eu-trials-for-one-time-weight-loss-gene-therapy/] * Matter Bio takes pancreatic therapy to clinic → https://longevity.technology/news/matter-bio-takes-pancreatic-therapy-to-clinic/ [https://longevity.technology/news/matter-bio-takes-pancreatic-therapy-to-clinic/] * New data suggests plaque damage can be cleared → https://longevity.technology/news/new-data-suggests-plaque-damage-can-be-cleared/ [https://longevity.technology/news/new-data-suggests-plaque-damage-can-be-cleared/] * Microbiome medicine moves past wellness into clinics → https://longevity.technology/news/microbiome-medicine-moves-past-wellness-into-clinics/ [https://longevity.technology/news/microbiome-medicine-moves-past-wellness-into-clinics/] * ‘Equity in longevity is the entire ballgame’ → https://longevity.technology/news/equity-in-longevity-is-the-entire-ballgame/ [https://longevity.technology/news/equity-in-longevity-is-the-entire-ballgame/]

Valter Longo: Can Short Fasting Cycles Regenerate the Body?

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [https://qrco.de/bgXpKn] ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: fatty15.com/UNLOCKED [fatty15.com/UNLOCKED] ---------- Guests: Valter Longo Professor and Director at USC Longevity Institute Instagram: https://www.instagram.com/prof_valterlongo/ [https://www.instagram.com/prof_valterlongo/] Website: https://valterlongo.com/ [https://valterlongo.com/] ---------- What if a five-day diet could reset metabolism, regenerate tissue, and challenge decades of nutrition dogma? Phil Newman and Dr. Nina Patrick sit down with Valter Longo, USC Longevity Institute researcher and architect of the fasting mimicking diet, to explore how short, periodic fasting cycles may interact with aging biology, insulin signaling, and tissue regeneration. Together they break down how the fasting mimicking diet differs from water fasting and simple calorie restriction, and why its plant based, low protein, low sugar, and high fat composition is designed to maintain protection while still triggering nutrient sensing pathways. Longo explains how in clinical and preclinical data, repeated cycles have shown improvements in insulin resistance, reductions in diabetes medication use by 60 to 70% in some cohorts, and measurable shifts in metabolic biomarkers compared to Mediterranean diet controls. The conversation also explores mechanistic findings, including autophagy activation peaking around day five in human studies, stem cell associated regeneration signals, and embryonic like gene expression patterns observed in multiple organ systems. In animal models, these cycles have been associated with pancreatic regeneration, kidney repair after induced damage, and normalization of cholesterol and glucose regulation. In this episode, you’ll learn: * Autophagy activation and peak biological signaling observed around day five in human fasting mimicking protocols * Clinical trials in diabetes showing 60 to 70% reduction in medication use within one year in some populations * Animal studies showing reversal of severe metabolic dysfunction with monthly fasting mimicking cycles * Protein restriction and mTOR IGF-1 signaling pathways repeatedly linked with lifespan extension across multiple species * Risk discussion around prolonged fasting triggering energy conserving metabolic adaptation states If you want to understand how structured fasting protocols may interact with aging pathways, metabolic disease, and regenerative biology, this episode connects clinical evidence with evolutionary and mechanistic frameworks shaping modern longevity science. Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping human healthspan.

Can Longevity Disrupt Hospitals From Within? — Longevity News Roundup — Week 20, 2026

Hosts: Phil Newman: https://qrco.de/bgXpNY [https://qrco.de/bgXpNY] Nina Patrick: ⁠⁠https://qrco.de/bgXpKn [https://qrco.de/bgXpKn] ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: https://partners.fatty15.com/UNLOCKED [https://partners.fatty15.com/UNLOCKED] ---------- In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GLP-1 drugs in progressive MS, Executive Health as a gateway to longevity care, AI-assisted skin regeneration, lab-grown red blood cells, and convergence in aging biomarkers. * Neuraly’s NLY01 dosed its first Phase 2 patient with progressive MS in the 120-person, 96-week TAGMS trial. Instead of tracking relapse rates, researchers will use MRI-measured brain atrophy as the primary endpoint to determine whether the GLP-1 receptor agonist can slow neurodegeneration after inflammation is controlled. * Biograph’s six-hour executive assessment compresses what they describe as three months of diagnostics into a single visit. Advanced imaging, biomarker panels, cardiac testing, biological age metrics, and cancer screening are bundled into one experience followed by a personalized action plan. * ROKIT Healthcare presented one to two-year follow-up data showing sensory restoration, minimal scarring, functional recovery, and zero cancer recurrence after AI-assisted autologous skin reconstruction. The platform uses a patient’s own fat-derived cells combined with AI-guided bioprinting to recreate tissue that behaves like original skin. * Hospitals are recognizing that prevention-focused longevity care could erode revenue from late-stage cardiometabolic and surgical interventions. At the same time, they already possess the imaging, labs, multidisciplinary teams, and care coordination required to deliver structured midlife risk assessment programs. * Scarlet Therapeutics raised $4 million in seed funding after demonstrating that lab-grown red blood cells survive in circulation as long as donor-derived cells. The company is developing applications that include universal transfusion supply, therapeutic carrier cells, and engineered red blood cells designed for enhanced biological function. * Steve Horvath argues that apparent biomarker chaos is narrowing toward a smaller set of aging measures that consistently predict mortality, disease risk, and functional decline. This convergence is critical for trials, clinics, and employer programs that need reliable endpoints to justify prevention strategies. ---------- News & References: * GLP-1 drug enters trial for progressive multiple sclerosis → https://longevity.technology/news/glp-1-drug-enters-trial-for-progressive-multiple-sclerosis/ [https://longevity.technology/news/glp-1-drug-enters-trial-for-progressive-multiple-sclerosis/] * Executive Health program condenses three months of testing into six hours → https://longevity.technology/news/executive-health-program-condenses-three-months-of-testing-into-six-hours/ [https://longevity.technology/news/executive-health-program-condenses-three-months-of-testing-into-six-hours/] * AI regenerative medicine targets skin recovery → https://longevity.technology/news/ai-regenerative-medicine-targets-skin-recovery/ [https://longevity.technology/news/ai-regenerative-medicine-targets-skin-recovery/] * Hospitals confront longevity’s quiet disruption → https://longevity.technology/news/hospitals-confront-longevitys-quiet-disruption/ [https://longevity.technology/news/hospitals-confront-longevitys-quiet-disruption/] * Scarlet raises $4m as lab-grown blood matches donor cell survival → https://longevity.technology/news/scarlet-raises-4m-as-lab-grown-blood-matches-donor-cell-survival/ [https://longevity.technology/news/scarlet-raises-4m-as-lab-grown-blood-matches-donor-cell-survival/] * ‘We are not at consensus but we are at convergence’ → https://longevity.technology/news/we-are-not-at-consensus-but-we-are-at-convergence/ [https://longevity.technology/news/we-are-not-at-consensus-but-we-are-at-convergence/]